{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Zevra Therapeutics, Inc.
Zevra Therapeutics Experiences Revision in Stock Evaluation Amid Strong Market Performance
Zevra Therapeutics, Inc. has recently revised its evaluation amid changing market conditions. The company’s stock price has risen, and it has achieved a significant annual return, outperforming the S&P 500. Technical indicators show a mix of bullish and mildly bearish trends, reflecting its competitive position in the market.
Is Zevra Therapeutics, Inc. technically bullish or bearish?
As of October 24, 2025, Zevra Therapeutics, Inc. shows a mildly bullish trend with positive momentum from MACD and moving averages, but caution is advised due to mixed signals from KST and Dow Theory.
Is Zevra Therapeutics, Inc. overvalued or undervalued?
As of October 3, 2023, Zevra Therapeutics, Inc. is considered attractive due to its undervalued financial metrics, including a P/E ratio of 15.2 and a P/B ratio of 1.8, which are lower than peers like Acadia Pharmaceuticals and Zymeworks, and its recent stock performance has outpaced the Sensex.
Is Zevra Therapeutics, Inc. technically bullish or bearish?
As of November 1, 2023, there is insufficient technical data for Zevra Therapeutics, Inc. to determine a bullish or bearish outlook.
What does Zevra Therapeutics, Inc. do?
Zevra Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $20 million and a net loss of $3 million as of March 2025. Key financial metrics include a market cap of $481.73 million and a return on equity of -232.30%.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
